Home Sectors Healthcare Present Fundamentals: Mallinckrodt (NYSE: MNK)

Present Fundamentals: Mallinckrodt (NYSE: MNK)

SHARE

Mallinckrodt trades as part of the drug manufacturers industry and trades as part of the healthcare sector. The company CEO is Mark C. Trudeau. Mallinckrodt is a drug manufacturing company that develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products. It operates in two segments including branded pharmaceuticals and generic drugs.

Previous Intraday Trading Performance:

The MNK stock showed a previous change of 7.17% with an open at 9.20 and a close of 9.71. It reached an intraday high of 9.78 and a low of 9.17.

PR Newswire:  RM LAW Announces Investigation of Mallinckrodt plc

Liquidity:

The stock has a market cap of $813.8m with 83.8m shares outstanding, of which the float is 82.6m shares. Trading volume reached 4,462,440 shares compared to its average volume of 3,844,370 shares. Based on the current average volume and close price, the trading liquidity is good.

Historical Trading Performance:

Over the last five trading days, Mallinckrodt shares returned 4.41% and in the past 30 trading days it returned -47.11%. Over three months, it changed -58.24%. In one year it has changed -43.08% and within that year its 52-week high was 36.65 and its 52-week low was 8.42. MNK stock is 15.32% above its 52 Week Low.

Our calculations show a 200 day moving average of 23.24 and a 50 day moving average of 17.07. Currently MNK stock is trading -58.21% below its 200 day moving average and may not be a good opportunity to buy as it may continue to trend down.

SeekingAlpha:  Wells Fargo likes Molina after Investor Day

Earnings:

The last annual fiscal EPS for the company was reported at -42.93 that ended on 31st of December 2018. Based on 8 analyst estimates, the consensus EPS for the next quarter is 1.79. The TTM EPS is 7.37, which comes to a TTM PE of 1.32.

Below was the last reported quarterly diluted earnings per share:

1stQtr of 2019 (Reported on 05/07/2019): 1.83
4thQtr of 2018 (Reported on 02/26/2019): -44.64
3rdQtr of 2018 (Reported on 11/06/2018): 1.34
2ndQtr of 2018 (Reported on 08/07/2018): 0.19
1stQtr of 2018 (Reported on 05/08/2018): -0.21

Base on our calculations, the intrinsic value per share is 64.49, which means it is possibly undervalued and has a margin of safety of 84.94%.

Indicators to Watch:

Short-interest was 28,836,515, which was 34.41% of shares outstanding. The short-interest ratio or days-to-cover ratio was 10.06. This stock has a high level of short interest and may fall in value in the near term.

The current calculated beta is 2.40.

PR Newswire:  Mallinckrodt to Present at Raymond James Life Sciences and Medtech Conference

Fundamental Indicators:

Based on last reported financials, the company’s return on equity is -76.83%, return on assets is -27.82%, price-to-sales is 0.26 and price-to-book is 0.25.

Company Scores:

All scores are out of six:
 3  :Valuation Score
 0  :Past Performance Score
 1  :Financial Strength Score
 3  :Future Growth Score
 0  :Dividend Score
 1  :Overall Score

SHARE
John Jones
Worked for several Wall Street firms: Salomon Smith Barney, UBS, and Charles Schwab. Has developed skills and gained extensive experience over the years that is used today to uncover winning penny stocks.Also was an attorney for small businesses in Scottsdale, Arizona. That experience and understanding of law provides a unique perspective and edge in discovering quality companies in various industries.